Announcement • Jun 23
Terumo Corporation to Report Q1, 2027 Results on Aug 07, 2026 Terumo Corporation announced that they will report Q1, 2027 results on Aug 07, 2026 Buy Or Sell Opportunity • May 25
Now 21% undervalued Over the last 90 days, the stock has risen 17% to €12.41. The fair value is estimated to be €15.74, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 11% over the last 3 years. Earnings per share has grown by 14%. For the next 3 years, revenue is forecast to grow by 6.0% per annum. Earnings are also forecast to grow by 11% per annum over the same time period. Valuation Update With 7 Day Price Move • May 22
Investor sentiment improves as stock rises 26% After last week's 26% share price gain to €12.76, the stock trades at a forward P/E ratio of 22x. Average forward P/E is 17x in the Medical Equipment industry in Germany. Total loss to shareholders of 3.8% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €15.81 per share. Reported Earnings • May 20
Full year 2026 earnings released: EPS: JP¥92.14 (vs JP¥79.01 in FY 2025) Full year 2026 results: EPS: JP¥92.14 (up from JP¥79.01 in FY 2025). Revenue: JP¥1.13t (up 9.2% from FY 2025). Net income: JP¥135.9b (up 16% from FY 2025). Profit margin: 12% (in line with FY 2025). Revenue is forecast to grow 6.0% p.a. on average during the next 3 years, compared to a 5.9% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings. Board Change • May 20
Less than half of directors are independent Following the recent departure of a director, there are only 4 independent directors on the board. The company's board is composed of: 4 independent directors. 5 non-independent directors. Independent Director Mari Kogiso was the last independent director to join the board, commencing their role in 2024. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Announcement • May 15
Terumo Corporation, Annual General Meeting, Jun 26, 2026 Terumo Corporation, Annual General Meeting, Jun 26, 2026. Announcement • Apr 02
Terumo Corporation to Report Q4, 2026 Results on May 15, 2026 Terumo Corporation announced that they will report Q4, 2026 results on May 15, 2026 Announcement • Dec 17
Terumo Corporation to Report Q3, 2026 Results on Feb 13, 2026 Terumo Corporation announced that they will report Q3, 2026 results on Feb 13, 2026 Announcement • Oct 30
Terumo Corporation (TSE:4543) completed the acquisition of remaining 99.5% stake in OrganOx Limited from a group of shareholders. Terumo Corporation (TSE:4543) has entered into a definitive agreement to acquire remaining 99.5% stake in OrganOx Limited from a group of shareholders for $1.5 billion on August 23, 2025. Upon completion of the transaction, OrganOx will become a wholly owned subsidiary of Terumo. The transaction will be funded from cash on hand and borrowings.
For the period ending December 31, 2024, OrganOx Limited reported total revenue of $69.14 million and EBIT of $9.01 million. As of December 31, 2024, OrganOx Limited reported total assets of $96.9 million and total common equity of $71.56 million.
The transaction is subject to approval by regulatory board / committee. The transaction is expected to close in FY2025.
Perella Weinberg Partners and Piper Sandler served as OrganOx’s financial advisors and Robbie McLaren, Ross McAloon, Charles Ruck, Elizabeth Richards, Betty Pang, Chad Jennings, Sean Finn, Maj Vaseghi, Kendall Burnett, Hector Armengod, Patrick English, Catherine Hein and Philipp Studt of Latham & Watkins acted as legal counsel to OrganOx in this transaction.
Terumo Corporation (TSE:4543) completed the acquisition of remaining 99.5% stake in OrganOx Limited from a group of shareholders on October 29, 2025. Announcement • Oct 24
Terumo Interventional Systems Announces its New OPUSWAVE Dual Sensor Imaging System and DualView®? Imaging Catheter Receive FDA 510(k) Clearance Terumo Interventional Systems (TIS) has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its OPUSWAVE®? Dual Sensor Imaging System. The OPUSWAVE Imaging System features the DualView®? imaging catheter, which also received FDA 510(k) clearance. The OPUSWAVE imaging System combines Optical Frequency Domain Imaging (OFDI) and intravascular ultrasound (IVUS) to enable simultaneous views, offering physicians the ability to comprehensively evaluate coronary artery disease (CAD). While this marks Terumo's imaging debut in the US market, the company is already a recognized leader in the single modality imaging space in Japan, where adoption of imaging in percutaneous coronary intervention (PCI) procedures is the highest in the world. What makes the OPUSWAVE Imaging System unique is the DualView imaging catheter, which offers a 150mm maximum pullback length. It also has a 2.6 Fr. imaging profile, 6 Fr. guide compatibility, advanced hydrophilic coating, and a variable pullback speed of up to 40mm/second in dual mode. Announcement • Sep 19
Terumo Corporation to Report Q2, 2026 Results on Nov 12, 2025 Terumo Corporation announced that they will report Q2, 2026 results on Nov 12, 2025 Announcement • Aug 25
Terumo Corporation (TSE:4543) has entered into a definitive agreement to acquire 99.5% stake in OrganOx Limited from a group of shareholders in a transaction valued at $1.5 billion. Terumo Corporation (TSE:4543) has entered into a definitive agreement to acquire 99.5% stake in OrganOx Limited from a group of shareholders in a transaction valued at $1.5 billion on August 23, 2025. Upon completion of the transaction, OrganOx will become a wholly owned subsidiary of Terumo.
For the period ending December 31, 2024, OrganOx Limited reported total revenue of $69.14 million and EBIT of $9.01 million. As of December 31, 2024, OrganOx Limited reported total assets of $96.9 million and total common equity of $71.56 million.
The transaction is subject to approval by regulatory board / committee.
Perella Weinberg Partners and Piper Sandler served as OrganOx’s financial advisors and Latham & Watkins acted as legal counsel to OrganOx in this transaction. Announcement • Jun 24
Terumo Corporation to Report Q1, 2026 Results on Aug 07, 2025 Terumo Corporation announced that they will report Q1, 2026 results on Aug 07, 2025 Announcement • Jun 03
Terumo Neuro Announces EMEA Commercial Availability of the SOFIA™? Flow 88 Neurovascular Aspiration Catheter Terumo Neuro announced the commercial availability of the SOFIA Flow 88 Neurovascular Aspiration Catheter, expanding the company's stroke portfolio with a new large-bore catheter engineered for reliability, procedural flexibility, and physician control. The launch builds on the proven clinical performance and global legacy of the SOFIA™? Catheter line, which has supported more than 500,000 procedures across 170 countries over the past decade. Terumo Neuro is showcasing its complete line of stroke solutions at LINNC Paris this week at Le Carrousel du Louvre, booth number 8. Leveraging more than ten years of neurovascular catheter innovation, physician partnerships and proven clinical performance1-9, the SOFIA™? 88 Neurovascular As inspiration Catheter offers an 0.088-inch inner diameter with proprietary engineering enhancements designed to provide the following benefits: Reach with Confidence - Reliable trackability through challenging anatomy via optimized transition zones and a soft, atraumatic distal tip. Support to Go the Distance - Proximal stability for procedural ease with both short and long sheaths. Atraumatic by Design - Flexibility and reinforcement throughout the entire working length to minimize vessel trauma and support smooth navigation. Engage the Clot with Confidence - Highly compliant proprietary SOFIA tip beyond the marker band expands conforming to the clot. Aspirate with Confidence - Next generation SOFIA technology with nitinol braid and coil reinforcement maintains lumen integrity. The SOFIA™ 88 Neurovascular Aspiration Catheter is compatible with the SOFIA™ Plus 6F Aspiration Catheter and supports integration into existing aspiration strategies. Clinical evidence from the SOFAST registry & the SESAME trial—evaluating the SOFIA™ Plus 6F as a first-line approach—demonstrated strong results across speed, efficacy, and safety and overall clinical outcomes. The new SOFIA™ 88 Catheter also seamlessly complements the company's broader stroke solution portfolio, offering a fully integrated approach across aspiration, access, retrieval, and navigation: SOFIA™ and SOFIA™ Plus Aspiration Catheters – Renowned for trackability and clinical performance, ERIC™ Retrieval Device – Designed for thrombus control, procedural efficiency, and versatility, BOBBY™ Balloon Guide Catheter – Reliable flow arrest with streamlined preparation, optimized compatibility and next-generation balloon technology, WEDGE™ Microcatheter – A navigation aid that minimizes ledge effect, HEADWAY™ Microcatheters – Low-profile outer diameter, providing versatility, reliability, and fast access, and TRAXCESS™ Guidewires – Soft-tip design for challenging anatomies. Announcement • May 28
Terumo Interventional Systems, Division of Terumo Corporation, Announces Commercial Availability of its ROADSAVER Carotid Stent System Terumo Interventional Systems (TIS), a division of Terumo Corporation, announced the early commercial availability of its FDA-approved ROADSAVER Carotid Stent System. Indicated for use with the Nanoparasol®? Embolic Protection System, ROADSAVER Stent System addresses carotid artery stenosis in patients with increased risk of adverse events following carotid endarterectomy. ROADSAver Stent System is the only carotid artery stenting (CAS) device with an innovative, dual-layer micromesh. It is designed as a closed-cell stent with the flexibility of an open-cell stent, providing increased flexibility and wall apposition in complex anatomies. It is also the first dual-layer micromesh carotid stent approved in the United States, and the only carotid stent system designed to contain plaque to the vessel wall and prevent plaque protrusion, protecting against distal embolization. Available in sizes from 5 to 10 mm in width and 22 to 47 mm in length, ROADSAVER StENT System has a rapid-exchange shaft length of 143 cm. It is also fully re-sheathable and repositionable - even after 50% of the stent's length is deployed. Another important feature is the product's low-profile 5Fr design, which enhances its crossability. Limited market release of the ROADSAVER CarotID Stent System is planned for summer 2025, with full market release anticipated in fall 2025. Announcement • May 14
Terumo Corporation, Annual General Meeting, Jun 24, 2025 Terumo Corporation, Annual General Meeting, Jun 24, 2025. Announcement • Apr 17
Terumo Blood and Cell Technologies Names Patrick Daly as Chief Business Officer Terumo Blood and Cell Technologies (Terumo BCT) announced the addition of Patrick Daly as its Chief Business Officer as the company continues to expand its capabilities to meet evolving market segments. Daly joins Terumo BCT with over 30 years of business and healthcare industry experience, both domestically and internationally. Most recently, he built the MedTech Global Data franchise at IQVIA, a provider of technology solutions to the life sciences industry. Daly has spent his career building commercial capabilities to deliver organic and inorganic growth. Before joining IQVIA, he was President and CEO of Cohera Medical, and he remains an independent Board Director for BioStem Technologies. He has held successive senior leadership roles in strategic marketing, sales and business development across various regions and businesses of Johnson &Johnson. He earned his Bachelor of Science in Foreign Area Studies from the U.S. Military Academy at West Point. Announcement • Mar 20
Terumo Corporation to Report Fiscal Year 2025 Results on May 14, 2025 Terumo Corporation announced that they will report fiscal year 2025 results on May 14, 2025 Announcement • Dec 12
Terumo Corporation to Report Q3, 2025 Results on Feb 13, 2025 Terumo Corporation announced that they will report Q3, 2025 results on Feb 13, 2025 Announcement • Dec 03
Terumo Interventional Systems Announces Launch of Its R2p Navicross Peripheral Support Catheter Terumo Interventional Systems (TIS), a division of Terumo Corporation announced the launch and commercial availability of its R2P™ NaviCross® peripheral support catheter in the U.S., further expanding the company's radial-to-peripheral (R2P) portfolio. The R2P NaviCross catheter, now available in a 200 cm length, is designed for optimized performance in R2P procedures. Its double-braided, stainless-steel construction is engineered for superior trackability and torque control for lesion crossing in more complex procedures. The new 200 cm R2P NaviCross catheter rounds out the existing R2P portfolio, including the R2P Destination Slender™ guiding sheath, R2P SlenGuide™ guiding catheter, R2P Misago® self-expanding peripheral stent, and R2P Metacross™ RX and R2P Crosstella™ RX dilatation catheters – giving physicians the confidence to complete almost any PAD procedure from the wrist. Reported Earnings • Nov 09
Second quarter 2025 earnings released: EPS: JP¥19.74 (vs JP¥18.49 in 2Q 2024) Second quarter 2025 results: EPS: JP¥19.74 (up from JP¥18.49 in 2Q 2024). Revenue: JP¥250.5b (up 9.6% from 2Q 2024). Net income: JP¥29.3b (up 6.4% from 2Q 2024). Profit margin: 12% (in line with 2Q 2024). Revenue is forecast to grow 5.8% p.a. on average during the next 3 years, compared to a 6.0% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has remained flat, which means it is significantly lagging earnings. Announcement • Sep 25
Terumo Corporation to Report Q2, 2025 Results on Nov 07, 2024 Terumo Corporation announced that they will report Q2, 2025 results on Nov 07, 2024 Upcoming Dividend • Sep 20
Upcoming dividend of JP¥13.00 per share Eligible shareholders must have bought the stock before 27 September 2024. Payment date: 04 December 2024. Payout ratio is a comfortable 28% and this is well supported by cash flows. Trailing yield: 1.0%. Lower than top quartile of German dividend payers (4.8%). Lower than average of industry peers (1.9%). Announcement • Aug 30
Terumo Corporation (TSE:4543) announces an Equity Buyback for 15,000,000 shares, representing 1.01% for ¥30,000 million. Terumo Corporation (TSE:4543) announces a share repurchase program. Under the program, the company will repurchase up to 15,000,000 shares, representing 1.01% of its issued share capital, for ¥30,000 million. The purpose of the program is to increase shareholder returns, improve capital efficiency, and mitigate the impact on stock supply and demand associated with the offering of our common stock. The repurchased shares will be cancelled. The program will run until December 30, 2024. As of June 30, 2024, the company had 1,484,855,220 shares in issue (excluding treasury stock) and 5,842,060 shares in treasury. Reported Earnings • Aug 09
First quarter 2025 earnings released: EPS: JP¥22.82 (vs JP¥15.14 in 1Q 2024) First quarter 2025 results: EPS: JP¥22.82 (up from JP¥15.14 in 1Q 2024). Revenue: JP¥258.2b (up 20% from 1Q 2024). Net income: JP¥33.9b (up 50% from 1Q 2024). Profit margin: 13% (up from 11% in 1Q 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 5.5% p.a. on average during the next 3 years, compared to a 6.5% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings. Declared Dividend • Jul 11
Final dividend of JP¥13.00 announced Shareholders will receive a dividend of JP¥13.00. Ex-date: 27th September 2024 Payment date: 4th December 2024 Dividend yield will be 82%, which is higher than the industry average of 1.7%. Sustainability & Growth Dividend is covered by both earnings (31% earnings payout ratio) and cash flows (57% cash payout ratio). The dividend has increased by an average of 14% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. EPS is expected to grow by 42% over the next 3 years, which should provide support to the dividend and adequate earnings cover. Reported Earnings • Jul 05
Full year 2024 earnings released: EPS: JP¥71.50 (vs JP¥59.50 in FY 2023) Full year 2024 results: EPS: JP¥71.50 (up from JP¥59.50 in FY 2023). Revenue: JP¥921.9b (up 12% from FY 2023). Net income: JP¥106.4b (up 19% from FY 2023). Profit margin: 12% (in line with FY 2023). Revenue is forecast to grow 6.0% p.a. on average during the next 3 years, compared to a 6.6% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings. Board Change • Jul 02
Less than half of directors are independent There are 5 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 5 independent directors. 6 non-independent directors. Independent Outside Director Keiya Ozawa was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Buy Or Sell Opportunity • Jun 05
Now 21% overvalued Over the last 90 days, the stock has fallen 11% to €15.70. The fair value is estimated to be €12.98, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 13% over the last 3 years. Earnings per share has grown by 6.3%. For the next 3 years, revenue is forecast to grow by 5.9% per annum. Earnings are also forecast to grow by 12% per annum over the same time period. Announcement • Jun 03
Terumo Corporation to Report Q1, 2025 Results on Aug 08, 2024 Terumo Corporation announced that they will report Q1, 2025 results on Aug 08, 2024 Announcement • May 29
Terumo Cardiovascular Announces 510(K) Clearance for the CDI Oneview™? Monitoring System Terumo Cardiovascular announced that the U.S. Food and Drug Administration has granted 510(k) clearance for the CDI OneView Monitoring System. The next-generation CDI Systems platform provides visibility of key patient parameters during cardiopulmonary bypass surgery, critical to perfusion safety and improving patient outcomes. The new CDI OneView System measures or displays up to 22 key parameters, the newest of which are measured flow (Q), cardiac index (CI), regional cerebral oxygen saturation (rSO2), oxygen extraction ratio (O2ER), Area Under the DO2 Curve (AUC), and measured arterial oxygen saturation (SaO2). This innovative system offers maximum configurability and flexibility in how the parameters can be viewed and prioritized to best suit clinical needs and preferences, while continuing to provide the critical information on which clinicians have come to rely. New features and functions of Terumo's latest patient parameter monitoring system were influenced by extensive perfusionist input from leading global cardiovascular institutions. In response to the growing needs of healthcare providers, the new CDI OneView System now provides real-time O2ER, CI, VO2 and DO2 information to help perfusionists maintain a safe threshold for those parameters. Independently published and reviewed clinical research indicates that maintaining optimal levels during cardiopulmonary bypass can help to reduce the incidence of acute kidney injury. Reported Earnings • May 16
Full year 2024 earnings released: EPS: JP¥71.50 (vs JP¥59.50 in FY 2023) Full year 2024 results: EPS: JP¥71.50 (up from JP¥59.50 in FY 2023). Revenue: JP¥921.9b (up 12% from FY 2023). Net income: JP¥106.4b (up 19% from FY 2023). Profit margin: 12% (in line with FY 2023). Revenue is forecast to grow 5.3% p.a. on average during the next 3 years, compared to a 6.9% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 6% per year whereas the company’s share price has increased by 2% per year. Upcoming Dividend • Mar 21
Upcoming dividend of JP¥22.00 per share Eligible shareholders must have bought the stock before 28 March 2024. Payment date: 28 June 2024. Payout ratio is a comfortable 32% and this is well supported by cash flows. Trailing yield: 0.8%. Lower than top quartile of German dividend payers (4.9%). Lower than average of industry peers (1.7%). Announcement • Mar 17
Terumo Corporation to Report Fiscal Year 2024 Results on May 14, 2024 Terumo Corporation announced that they will report fiscal year 2024 results on May 14, 2024 Announcement • Feb 09
Terumo Corporation Revises Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2024 Terumo Corporation revised consolidated earnings guidance for the fiscal year ending March 31, 2024. For the year, the company expects revenue to be JPY 906,000 million. Operating profit to be JPY 140,000 million. Profit attributable to owners of parent to be JPY 105,000 million. Earnings per share to be JPY 141.18. Reported Earnings • Feb 08
Third quarter 2024 earnings released: EPS: JP¥40.06 (vs JP¥39.97 in 3Q 2023) Third quarter 2024 results: EPS: JP¥40.06. Revenue: JP¥239.1b (up 11% from 3Q 2023). Net income: JP¥29.8b (flat on 3Q 2023). Profit margin: 13% (down from 14% in 3Q 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 5.7% p.a. on average during the next 3 years, compared to a 6.5% growth forecast for the Medical Equipment industry in Germany. Buy Or Sell Opportunity • Feb 08
Now 28% overvalued after recent price rise Over the last 90 days, the stock has risen 26% to €32.80. The fair value is estimated to be €25.72, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 13% over the last 3 years. Earnings per share has grown by 6.1%. For the next 3 years, revenue is forecast to grow by 5.8% per annum. Earnings are also forecast to grow by 12% per annum over the same time period. Announcement • Feb 07
Terumo Corporation Provides Dividend Guidance for the Fiscal Year Ending March 31, 2024 Terumo Corporation provided dividend guidance for the fiscal year ending March 31, 2024. For the year, the company expects dividend of JPY 22.00 per share against JPY 21.00 per share paid for the same period a year ago. Announcement • Dec 03
Terumo Corporation to Report Q3, 2024 Results on Feb 07, 2024 Terumo Corporation announced that they will report Q3, 2024 results on Feb 07, 2024 Reported Earnings • Nov 17
Second quarter 2024 earnings released: EPS: JP¥36.99 (vs JP¥23.75 in 2Q 2023) Second quarter 2024 results: EPS: JP¥36.99 (up from JP¥23.75 in 2Q 2023). Revenue: JP¥228.6b (up 11% from 2Q 2023). Net income: JP¥27.5b (up 54% from 2Q 2023). Profit margin: 12% (up from 8.7% in 2Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 6.0% p.a. on average during the next 3 years, compared to a 6.2% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings. Announcement • Oct 01
Terumo Corporation to Report Q2, 2024 Results on Nov 14, 2023 Terumo Corporation announced that they will report Q2, 2024 results on Nov 14, 2023 Upcoming Dividend • Sep 21
Upcoming dividend of JP¥22.00 per share at 1.1% yield Eligible shareholders must have bought the stock before 28 September 2023. Payment date: 05 December 2023. Payout ratio is a comfortable 33% and the cash payout ratio is 100%. Trailing yield: 1.1%. Lower than top quartile of German dividend payers (4.8%). Lower than average of industry peers (2.0%). Announcement • Aug 10
Terumo Corporation (TSE:4543) announces an Equity Buyback for 5,000,000 shares, representing 0.67% for ¥20,000 million. Terumo Corporation (TSE:4543) announces a share repurchase program. Under the program, the company will repurchase up to 5,000,000 shares, representing 0.67% of its issued share capital, for ¥20,000 million. The purpose of the program is to expand shareholder returns and improve capital efficiency. The repurchased shares will be cancelled. The program will run until March 8, 2024. As of June 30, 2023, the company had 744,644,147 shares in issue (excluding treasury stock) and 3,038,393 shares in treasury. Reported Earnings • Aug 10
First quarter 2024 earnings released: EPS: JP¥30.28 (vs JP¥29.61 in 1Q 2023) First quarter 2024 results: EPS: JP¥30.28 (up from JP¥29.61 in 1Q 2023). Revenue: JP¥215.3b (up 9.1% from 1Q 2023). Net income: JP¥22.5b (flat on 1Q 2023). Profit margin: 11% (in line with 1Q 2023). Revenue is forecast to grow 5.6% p.a. on average during the next 3 years, compared to a 6.3% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings. Announcement • Jun 21
Terumo Corporation to Report Q1, 2024 Results on Aug 09, 2023 Terumo Corporation announced that they will report Q1, 2024 results on Aug 09, 2023 Reported Earnings • May 16
Full year 2023 earnings released: EPS: JP¥119 (vs JP¥117 in FY 2022) Full year 2023 results: EPS: JP¥119 (up from JP¥117 in FY 2022). Revenue: JP¥820.2b (up 17% from FY 2022). Net income: JP¥89.3b (flat on FY 2022). Profit margin: 11% (down from 13% in FY 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 5.7% p.a. on average during the next 3 years, compared to a 6.4% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings. Announcement • May 16
Terumo Corporation, Annual General Meeting, Jun 27, 2023 Terumo Corporation, Annual General Meeting, Jun 27, 2023. Upcoming Dividend • Mar 23
Upcoming dividend of JP¥21.00 per share at 1.2% yield Eligible shareholders must have bought the stock before 30 March 2023. Payment date: 23 June 2023. Payout ratio is a comfortable 32% and this is well supported by cash flows. Trailing yield: 1.2%. Lower than top quartile of German dividend payers (4.7%). Lower than average of industry peers (1.7%). Reported Earnings • Feb 10
Third quarter 2023 earnings released: EPS: JP¥39.97 (vs JP¥28.70 in 3Q 2022) Third quarter 2023 results: EPS: JP¥39.97 (up from JP¥28.70 in 3Q 2022). Revenue: JP¥214.7b (up 20% from 3Q 2022). Net income: JP¥29.9b (up 38% from 3Q 2022). Profit margin: 14% (up from 12% in 3Q 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 5.8% p.a. on average during the next 3 years, compared to a 6.2% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings. Reported Earnings • Nov 16
Second quarter 2023 earnings released: EPS: JP¥23.75 (vs JP¥29.22 in 2Q 2022) Second quarter 2023 results: EPS: JP¥23.75 (down from JP¥29.22 in 2Q 2022). Revenue: JP¥206.0b (up 19% from 2Q 2022). Net income: JP¥17.9b (down 19% from 2Q 2022). Profit margin: 8.7% (down from 13% in 2Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 6.3% p.a. on average during the next 3 years, compared to a 6.2% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has remained flat whereas the company’s share price has fallen by 4% per year. Board Change • Nov 16
Less than half of directors are independent Following the recent departure of a director, there are only 5 independent directors on the board. The company's board is composed of: 5 independent directors. 6 non-independent directors. Independent Outside Director Keiya Ozawa was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Nov 12
Second quarter 2023 earnings released: EPS: JP¥23.75 (vs JP¥29.22 in 2Q 2022) Second quarter 2023 results: EPS: JP¥23.75 (down from JP¥29.22 in 2Q 2022). Revenue: JP¥206.0b (up 19% from 2Q 2022). Net income: JP¥17.9b (down 19% from 2Q 2022). Profit margin: 8.7% (down from 13% in 2Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 6.3% p.a. on average during the next 3 years, compared to a 6.2% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has remained flat whereas the company’s share price has fallen by 4% per year. Announcement • Nov 10
Terumo Corporation to Report Q3, 2023 Results on Nov 10, 2023 Terumo Corporation announced that they will report Q3, 2023 results on Nov 10, 2023 Announcement • Sep 28
Terumo Corporation to Report Q2, 2023 Results on Nov 10, 2022 Terumo Corporation announced that they will report Q2, 2023 results on Nov 10, 2022 Upcoming Dividend • Sep 22
Upcoming dividend of JP¥18.00 per share Eligible shareholders must have bought the stock before 29 September 2022. Payment date: 05 December 2022. Payout ratio is a comfortable 31% and this is well supported by cash flows. Trailing yield: 0.8%. Lower than top quartile of German dividend payers (5.1%). Lower than average of industry peers (1.8%). Announcement • Sep 09
Mitsui DM Sugar Holdings Co.,Ltd. (TSE:2109) agreed to acquire Enteral formula business of Terumo Corporation from Terumo Corporation (TSE:4543). Mitsui DM Sugar Holdings Co.,Ltd. (TSE:2109) agreed to acquire Enteral formula business of Terumo Corporation from Terumo Corporation (TSE:4543) on September 7, 2022. Announcement • Sep 08
NUTRI Co.,Ltd. entered into an agreement to acquire Nutritional food and related product assets of Terumo Corporation. NUTRI Co.,Ltd. entered into an agreement to acquire Nutritional food and related product assets of Terumo Corporation on September 7, 2022. Th asset transfer is scheduled for November 1, 2022. Reported Earnings • Aug 10
First quarter 2023 earnings released: EPS: JP¥29.61 (vs JP¥36.90 in 1Q 2022) First quarter 2023 results: EPS: JP¥29.61 (down from JP¥36.90 in 1Q 2022). Revenue: JP¥197.3b (up 15% from 1Q 2022). Net income: JP¥22.4b (down 20% from 1Q 2022). Profit margin: 11% (down from 16% in 1Q 2022). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 9.3%, compared to a 7.3% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 1% per year whereas the company’s share price has increased by 2% per year. Board Change • Jul 05
Less than half of directors are independent Following the recent departure of a director, there are only 5 independent directors on the board. The company's board is composed of: 5 independent directors. 6 non-independent directors. Independent Outside Director Keiya Ozawa was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Announcement • May 16
Terumo Announces Change in Indication for Dexcom G6 CGM System in Japan Terumo Corporation announces that the indication for the Dexcom G6 CGM System has changed in Japan as of May 10, 2022. With this new indication, the Dexcom G6 CGM System will be the only real-time continuous glucose monitoring system (RT-CGM) in Japan that can be used principally for day-to-day management of blood glucose levels without the adjunctive use of a blood glucose meter. The Dexcom G6 CGM System is a RT-CGM developed and manufactured by Dexcom Inc. Terumo holds the exclusive distribution agreement for this product in Japan, and it has been available for Japanese patients with diabetes since 2021. Users attach a small wearable sensor to the abdomen or other parts of the body so that glucose values are continuously measured and automatically transmitted every five minutes to a receiver or a smartphone with a dedicated app installed. Dexcom G6 CGM System users can constantly check their real-time glucose values and trends with a visualized graph. The system can also notify users when blood glucose values fall outside the target, as well as alert users when a severe hypoglycemic event is predicted. Previously in Japan the indication for Dexcom G6 CGM system was limited to "assisting" blood glucose meters. As such, a blood glucose meter was required for day-to-day diabetes management such as adjusting the amount of insulin dozes. With the change in indication, a blood glucose meter is only required "when necessary" and the Dexcom G6 CGM system can be utilized for users to make everyday treatment decisions. Reported Earnings • May 14
Full year 2022 earnings released: EPS: JP¥117 (vs JP¥102 in FY 2021) Full year 2022 results: EPS: JP¥117 (up from JP¥102 in FY 2021). Revenue: JP¥703.3b (up 15% from FY 2021). Net income: JP¥88.8b (up 15% from FY 2021). Profit margin: 13% (in line with FY 2021). Over the next year, revenue is forecast to grow 7.7%, compared to a 7.1% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 1% per year whereas the company’s share price has increased by 5% per year. Board Change • Apr 27
Less than half of directors are independent There are 5 new directors who have joined the board in the last 3 years. Of these new board members, 4 were independent directors. The company's board is composed of: 5 independent directors. 6 non-independent directors. Independent Outside Director Keiya Ozawa was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Announcement • Apr 08
Terumo Corporation to Report Fiscal Year 2022 Results on May 12, 2022 Terumo Corporation announced that they will report fiscal year 2022 results on May 12, 2022 Upcoming Dividend • Mar 23
Upcoming dividend of JP¥16.00 per share Eligible shareholders must have bought the stock before 30 March 2022. Payment date: 23 June 2022. Payout ratio is a comfortable 26% and this is well supported by cash flows. Trailing yield: 0.8%. Lower than top quartile of German dividend payers (3.6%). Lower than average of industry peers (1.1%). Upcoming Dividend • Mar 23
Upcoming dividend of JP¥16.00 per share Eligible shareholders must have bought the stock before 30 March 2022. Payment date: 23 June 2022. Payout ratio is a comfortable 26% and this is well supported by cash flows. Trailing yield: 0.8%. Lower than top quartile of German dividend payers (3.6%). Lower than average of industry peers (1.1%). Reported Earnings • Feb 10
Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations Third quarter 2022 results: EPS: JP¥28.70 (down from JP¥35.41 in 3Q 2021). Revenue: JP¥178.8b (up 8.2% from 3Q 2021). Net income: JP¥21.7b (down 19% from 3Q 2021). Profit margin: 12% (down from 16% in 3Q 2021). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Over the next year, revenue is forecast to grow 7.4%, compared to a 12% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has remained flat but the company’s share price has increased by 6% per year, which means it is well ahead of earnings. Announcement • Feb 10
Terumo Corporation, Annual General Meeting, Jun 22, 2022 Terumo Corporation, Annual General Meeting, Jun 22, 2022. Reported Earnings • Nov 05
Second quarter 2022 earnings released: EPS JP¥29.22 (vs JP¥23.63 in 2Q 2021) The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2022 results: Revenue: JP¥172.9b (up 14% from 2Q 2021). Net income: JP¥22.1b (up 24% from 2Q 2021). Profit margin: 13% (up from 12% in 2Q 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 3% per year but the company’s share price has increased by 16% per year, which means it is well ahead of earnings. Upcoming Dividend • Sep 22
Upcoming dividend of JP¥15.00 per share Eligible shareholders must have bought the stock before 29 September 2021. Payment date: 02 December 2021. Trailing yield: 0.6%. Lower than top quartile of German dividend payers (3.2%). Lower than average of industry peers (0.8%). Reported Earnings • Aug 05
First quarter 2022 earnings released: EPS JP¥36.90 (vs JP¥18.57 in 1Q 2021) The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2022 results: Revenue: JP¥171.7b (up 31% from 1Q 2021). Net income: JP¥27.9b (up 99% from 1Q 2021). Profit margin: 16% (up from 11% in 1Q 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 7% per year but the company’s share price has increased by 13% per year, which means it is well ahead of earnings. Reported Earnings • Jun 28
Full year 2021 earnings released: EPS JP¥102 (vs JP¥114 in FY 2020) The company reported a poor full year result with weaker earnings and revenues, although profit margins were flat. Full year 2021 results: Revenue: JP¥613.8b (down 2.4% from FY 2020). Net income: JP¥77.3b (down 9.3% from FY 2020). Profit margin: 13% (in line with FY 2020). Over the last 3 years on average, earnings per share has fallen by 9% per year but the company’s share price has increased by 11% per year, which means it is well ahead of earnings. Reported Earnings • May 14
Full year 2021 earnings released: EPS JP¥102 (vs JP¥114 in FY 2020) The company reported a poor full year result with weaker earnings and revenues, although profit margins were flat. Full year 2021 results: Revenue: JP¥613.8b (down 2.4% from FY 2020). Net income: JP¥77.3b (down 9.3% from FY 2020). Profit margin: 13% (in line with FY 2020). Over the last 3 years on average, earnings per share has fallen by 9% per year but the company’s share price has increased by 6% per year, which means it is well ahead of earnings. Upcoming Dividend • Mar 23
Upcoming dividend of JP¥14.00 per share Eligible shareholders must have bought the stock before 30 March 2021. Payment date: 26 June 2021. Trailing yield: 0.7%. Lower than top quartile of German dividend payers (3.3%). Lower than average of industry peers (1.0%). Announcement • Feb 25
Terumo Corporation (TSE:4543) signed definitive agreement to acquire All Assets from Health Outcomes Sciences, Inc. Terumo Corporation (TSE:4543) signed definitive agreement to acquire All Assets from Health Outcomes Sciences, Inc. on February 23, 2021. As part of the transaction, Terumo Corporation will also acquire ePRISM technology. Following the close, the ePRISM platform will be integrated into Terumo Business Edge. The transaction is expected to close in February 2021. Is New 90 Day High Low • Feb 20
New 90-day high: €36.40 The company is up 12% from its price of €32.40 on 20 November 2020. The German market is up 10.0% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Medical Equipment industry, which is up 22% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €21.12 per share. Announcement • Feb 08
Terumo Corporation Announces Clinical Study in Japan for Product Using Terumo's Automated Injection Device Developed in Collaboration with Kyowa Kirin Co., Ltd Terumo Corporation announced the completion of a clinical study in Japan for a product using Terumo's automated injection device developed in collaboration with Kyowa Kirin Co. Ltd. Kyowa Kirin initiated the clinical study in February 2020, to evaluate the safety of the product which combines the drug G-Lasta® (generic name: pegfilgrastim (genetical recombination)) and an automated injection device. G-Lasta is a drug for decreasing incidence of febrile neutropenia in patients receiving cancer chemotherapy, launched in Japan by Kyowa Kirin in 2014. The drug is generally administered at hospitals, at least one day after chemotherapy. This investigational product has a function to deliver G-Lasta into the patient's body after a specified time. By applying the device on the same day of chemotherapy, it is expected to alleviate the patient's burden of revisiting the hospital, and also reduce the workload of healthcare providers. Terumo's Alliance Division, a part of the General Hospital Company, is committed to developing partnerships with pharmaceutical companies. Based on Terumo's expertise on injection needles, syringes and other core technologies related to drug administration, the company will continue to meet the expanding needs of healthcare by developing novel drug delivery systems. Moving forward, Terumo will strive to promote an even better future for healthcare together with pharmaceutical companies. 